Great Diamond Partners LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Great Diamond Partners LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 335 shares of the biopharmaceutical company’s stock after selling 254 shares during the period. Great Diamond Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $352,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $26,000. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $28,000. Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $33,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on REGN. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Royal Bank of Canada restated an “outperform” rating and issued a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 22nd. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,101.00.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $927.33 on Wednesday. The company has a market capitalization of $102.23 billion, a price-to-earnings ratio of 24.56, a PEG ratio of 3.20 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals, Inc. has a 1 year low of $772.84 and a 1 year high of $1,211.20. The company’s 50 day simple moving average is $1,077.78 and its 200 day simple moving average is $1,041.48.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the previous year, the business earned $8.79 earnings per share. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

Insider Activity

In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.